

Søknadsinformasjon

Utlysning	Nordic Cancer Union Research Grant, 2015
Søknad	Nordic Collaborative Clinical Database Initiative and Allogeneic Stem Cell Transplantation Project for Myelodysplastic Syndromes
Søknadsid	176841
Innsendt av	Eva Hellström Lindberg

Oppgave: Progress report

Tilordnet	Eva Hellström Lindberg
Status	Arkivert
Opprettet	10.02.2017

RAPPORT

Briefly describe the project in a language understandable to non-scientists

The ultimate goal with the project is to seek to prevent Myelodysplastic syndrome (MDS) from developing and - to provide the best available treatment for every MDS patient in the Nordic region. A novel approach to improve outcome for patients undergoing allogeneic stem cell transplantation will be tested in a prospective study

1. We will establish a pan-Nordic database for MDS enabling the following specific questions
 - National and regional differences in incidence, risk profiles, and survival of MDS.
 - National and regional differences in the use and long-term outcome of allogeneic stem cell transplantation.
 - Validation of existing and novel prognostic scoring systems in a population-based MDS-registry.
 - National and regional differences in use of novel anti-MDS agents.
2. We will initiate a pan-Nordic study developing a new molecular platform for detecting early relapses after stem cell transplantation

Summarize the major findings of the project

1. All ethical permits are ready for the pan-Nordic database. Denmark and Sweden, where the national databases are most elaborate have initiated all 4 projects above-described
2. The NMDSG14B study was launch in Sweden September 2016 and has enrolled >10 patients. The ethical permit is ready in Norway (first patient enrolled) and pending in Denmark. The Finnish parallel study has recruited >5 patients. This is according to plan

Describe how the project has increased our knowledge of the prevention, cause and/or cure for cancer

1. The previous NCU project (2012-2014) has established next generation sequencing as a back bone of MDS diagnostics and prognostics, this is about to be incorporated into the Nordic Guidelines for MDS, new edition 2017.
2. The Nordic cohort of 500 sequenced patients will soon be ready for first publication.
3. In associated studies we have outlined the role of NGS in the choice of azacytidine treatment for higher-risk MDS and lenalidomide for patients with low-risk MDS and del(5q)
2. In the current project, we are using NGS to better understand MDS in the context of conventional risk factors.
3. We have also set a firm goal to prevent at least 30% of relapses after stem cell transplantation

Outline how Nordic cooperation has added value to this project

The Nordic MDS Group has worked together for more than 30 years. We meet twice yearly and are publishing joint studies more frequent than ever. We have also developed the website for increased functionality. The improvement in the knowledge around MDS had not been possible without NMDSG

List the publications resulting from the NCU research grant

Author(s), title, journal and edition	PMID (8 digits, only if possible)
<p>Garelius H, Johnston WT, Smith AG, et al, Crouch S, de Witte T, Hellström-Lindberg E. Erythropoiesis stimulating agents significantly delay the onset of a regular transfusion need in patients with lower-risk MDS and anemia. J Intern Med. 2016 Dec 7.</p>	27926979
<p>Progression in patients with low- and intermediate1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations.</p> <p>Scharenberg C, Giai V, Pellagatti A, Saft L, Dimitriou M, Jansson M, Jädersten M, Grandien A, Douagi I, Neuberg DS, LeBlanc K, Boulwood J, Karimi M, Jacobsen SE, Woll PS, Hellström-Lindberg E.</p> <p>Haematologica. 2016 Nov 24</p>	27884971
<p>Mutations in histone modulators are associated with prolonged survival during azacitidine therapy.</p> <p>Tobiasson M, McLornan DP, Karimi M, Dimitriou M, Jansson M, Ben Azenkoud A, Jädersten M, Lindberg G, Abdulkadir H, Kulasekararaj A, Ungerstedt J, Lennartsson A, Ekwall K, Mufti GJ, Hellström-Lindberg E.</p> <p>Oncotarget. 2016 Apr 19;7(16):22103-15</p>	26959885
<p>SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.</p> <p>Malcovati L, Karimi M, Papaemmanuil E, Ambaglio I, Jädersten M, Jansson M, Elena C, Galli A, Walldin G, Della Porta MG, Raaschou-Jensen K, Travaglino E, Kallenbach K, Pietra D, Ljungström V, Conte S, Boveri E, Invernizzi R, Rosenquist R, Campbell PJ, Cazzola M, Hellström Lindberg E.</p> <p>Blood. 2015 Jul 9;126(2):233-41</p>	25957392

Brief overview of expenditures for last year 1 vedlegg (Nordic MDS Group study expenditures 2016.docx)